
Bionano Genomics (BNGO) Stock Forecast & Price Target
Bionano Genomics (BNGO) Analyst Ratings
Bulls say
Bionano Genomics reported a significant increase in sales, with 7,233 nanochannel array flowcells sold in 2Q25, representing a 17% rise from the same quarter in the previous year. The company showcased strong growth in its consumables and software revenue streams, which increased by 16% year-over-year in 2Q25, leading to an overall 11% growth in combined revenue from consumables, software, and other services after adjustments. Furthermore, Bionano anticipates higher installation expectations for its OGM system in FY2025, projecting 20-25 installations, reflecting the company's expanding footprint in key markets, including the promising growth in Japan.
Bears say
Bionano Genomics faces several critical risks that contribute to a negative outlook on its stock, including lower-than-expected market uptake of its products and underutilization of installed systems, which may hinder revenue growth. Additionally, the company's potential inability to secure additional capital could restrict its operational capabilities, while the risk of dilution further complicates the financial landscape. The reliance on a conservative EV/Revenue multiple indicates an uncertain sales environment, reinforcing doubts about achieving projected financial performance in the near term.
This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.
Bionano Genomics (BNGO) Analyst Forecast & Price Prediction
Start investing in Bionano Genomics (BNGO)
Order type
Buy in
Order amount
Est. shares
0 shares